Lifesci Capital Has Negative Outlook of Liquidia Q3 Earnings

Liquidia Corporation (NASDAQ:LQDA) – Equities research analysts at Lifesci Capital lowered their Q3 2026 earnings per share estimates for Liquidia in a research note issued to investors on Tuesday, May 12th. Lifesci Capital analyst G. Maini now anticipates that the company will earn $0.66 per share for the quarter, down from their prior forecast of $0.85. Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Liquidia’s current full-year earnings is $2.14 per share.

Other equities analysts also recently issued reports about the stock. BTIG Research upped their price target on shares of Liquidia from $50.00 to $59.00 and gave the stock a “buy” rating in a research note on Monday. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Liquidia in a research note on Thursday, March 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a research note on Tuesday, April 21st. Zacks Research raised shares of Liquidia from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 5th. Finally, Wells Fargo & Company upped their price target on shares of Liquidia from $51.00 to $62.00 and gave the stock an “overweight” rating in a research note on Tuesday. Three analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Liquidia has an average rating of “Moderate Buy” and an average target price of $49.33.

Liquidia Trading Up 1.7%

NASDAQ LQDA opened at $57.59 on Thursday. Liquidia has a 1-year low of $11.85 and a 1-year high of $57.80. The company has a current ratio of 2.22, a quick ratio of 1.84 and a debt-to-equity ratio of 1.18. The company has a market capitalization of $5.12 billion, a PE ratio of 411.39 and a beta of 0.41. The firm’s fifty day simple moving average is $38.70 and its 200-day simple moving average is $35.54.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The business had revenue of $132.87 million for the quarter, compared to the consensus estimate of $119.44 million. The firm’s revenue for the quarter was up 4187.1% compared to the same quarter last year.

Institutional Investors Weigh In On Liquidia

A number of hedge funds have recently bought and sold shares of LQDA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Liquidia by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock valued at $556,000 after acquiring an additional 1,700 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Liquidia by 10.7% during the first quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock valued at $12,703,000 after acquiring an additional 82,955 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Liquidia by 15.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock valued at $1,796,000 after acquiring an additional 16,022 shares during the period. Creative Planning boosted its holdings in Liquidia by 40.7% during the second quarter. Creative Planning now owns 26,840 shares of the company’s stock valued at $334,000 after acquiring an additional 7,765 shares during the period. Finally, Legal & General Group Plc boosted its holdings in Liquidia by 13.4% during the second quarter. Legal & General Group Plc now owns 94,152 shares of the company’s stock valued at $1,174,000 after acquiring an additional 11,111 shares during the period. 64.54% of the stock is currently owned by institutional investors.

Insider Activity at Liquidia

In other Liquidia news, Director Stephen M. Bloch sold 318,893 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $50.23, for a total transaction of $16,017,995.39. Following the completion of the sale, the director directly owned 1,870,042 shares in the company, valued at $93,932,209.66. This represents a 14.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Michael Kaseta sold 139,390 shares of the company’s stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $40.14, for a total transaction of $5,595,114.60. Following the sale, the chief financial officer owned 353,356 shares of the company’s stock, valued at $14,183,709.84. This trade represents a 28.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 972,713 shares of company stock valued at $41,856,503. 25.60% of the stock is owned by corporate insiders.

Liquidia News Roundup

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reported Q1 results that topped expectations on both earnings and revenue, reinforcing the company’s commercialization progress and improving profitability. Liquidia Corporation Reports First Quarter 2026 Financial Results
• Positive Sentiment: Management said YUTREPIA net product sales rose 44% sequentially and outlined at least $1 billion in net revenue by 2027, which supports the stock’s growth narrative. YUTREPIA sales and 2027 revenue target
• Positive Sentiment: Several analysts turned more bullish after earnings, with firms including Needham, BTIG, and Wells Fargo raising price targets or reaffirming favorable ratings. Analyst price target updates
• Positive Sentiment: LQDA was added to Zacks’ Rank #1 Strong Buy list, adding momentum-driven support for the shares. Zacks Strong Buy list
• Neutral Sentiment: CEO Roger Jeffs and Director Stephen Bloch disclosed insider stock sales. The CEO’s sale was made under a pre-arranged 10b5-1 plan, while Bloch’s larger sale may still attract investor attention but does not necessarily signal a business deterioration. SEC filing
• Negative Sentiment: One recent research note suggested YUTREPIA’s launch momentum could be nearing a ceiling, which may raise questions about how long the current growth rate can persist. Rating downgrade article

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).